The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

More information: Robert Wood et al, Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Robert A. Wood, MD, FAAAAI, looks back on the first year of omalizumab’s use for food allergy. Patients often are allergic to multiple foods or to foods that are difficult to avoid. Perspective ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

Director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children’s Center, Robert Wood, MD led a clinical trial on omalizumab — an already FDA-approved drug ...

Robert Wood, the director of the Eudowood Division of Allergy, Immunology, and Rheumatology at Johns Hopkins Children’s Center, led a clinical trial on omalizumab—an already FDA-approved drug ...